Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...

Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 ...

DENVER, CO / ACCESS Newswire / July 8, 2025 / If you’ve spent any time online lately searching for genuine ways to burn ...

A MOUNJARO user has candidly opened up on what happened after she used fat jabs for just four weeks. Despite being “really happy” with losing two to three lbs a week on the injections, Megan ...

We spoke with healthcare experts to uncover the simple steps you can ... "Preventing adult-onset diabetes, high blood ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

For years, people living with obesity have been given the same basic advice: eat less, move more. But while this mantra may ...

Dr. David Geier joined Good morning Charleston Wednesday to break down a new study and talk about some of the myths surrounding a persons BMI and what measureme ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...